Skip to content
Kerendia(finerenone)
Kerendia (finerenone) is a small molecule pharmaceutical. Finerenone was first approved as Kerendia on 2021-07-09. It has been approved in Europe to treat chronic renal insufficiency and type 2 diabetes mellitus. It is known to target mineralocorticoid receptor.
Download report
Favorite
FDA Novel Drug Approvals 2021
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Kerendia
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Finerenone
Tradename
Company
Number
Date
Products
KERENDIABayerN-215341 RX2021-07-09
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
kerendiaNew Drug Application2021-07-09
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
FINERENONE, KERENDIA, BAYER HLTHCARE
2026-07-09NCE
2025-09-01M-279
Patent Expiration
Patent
Expires
Flag
FDA Information
Finerenone, Kerendia, Bayer Hlthcare
84361802029-04-12DS, DP
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03D: Aldosterone antagonists and other potassium-sparing agents
— C03DA: Aldosterone antagonists
— C03DA05: Finerenone
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436N181231512
Type 2 diabetes mellitusD003924EFO_0001360E11—2—158
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50331——7
Diabetic nephropathiesD003928EFO_0000401121——4
ProteinuriaD011507HP_0000093R80——2——2
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD0105992————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic retinopathyD003930EFO_0003770————22
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFINERENONE
INNfinerenone
Description
Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA).
Classification
Small molecule
Drug classaldosterone antagonists (spironolactone type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2
Identifiers
PDB—
CAS-ID1050477-31-0
RxCUI—
ChEMBL IDCHEMBL2181927
ChEBI ID—
PubChem CID60150535
DrugBankDB16165
UNII IDDE2O63YV8R (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
NR3C2
NR3C2
Organism
Homo sapiens
Gene name
NR3C2
Gene synonyms
MCR, MLR
NCBI Gene ID
4306
Protein name
mineralocorticoid receptor
Protein synonyms
aldosterone receptor, mineralocorticoid receptor 1, mineralocorticoid receptor 2, mineralocorticoid receptor delta, Nuclear receptor subfamily 3 group C member 2
Uniprot ID
Q96KQ9
Mouse ortholog
Nr3c2 (110784)
mineralocorticoid receptor (Q8VII8)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 824 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7 adverse events reported
View more details